11/22/2023 0 Comments 4d molecular therapeutics ipo"We are excited by the significant progress we have made across our large market product candidate portfolio in the second quarter," said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. 09, 2023 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics FDMT 4DMT, or the Company))) a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, today reported second quarter 2023 financial results and provided operational highlights. Strong balance sheet, closing the quarter with $310 million in cash, cash equivalents, and marketable securities, which includes net proceeds from upsized public offering of $138 million in common stock in May, expected to be sufficient to fund operations into the first half of 2026ĮMERYVILLE, Calif., Aug.Entered license agreement with Astellas Pharma in July and received $20 million upfront with potential future milestones of up to $942.5 million, including potential near-term development milestones of $15 million for the initial target.Anticipate multiple clinical data and regulatory interaction updates on lead clinical-stage product candidates 4D-150 in wet AMD and 4D-710 in cystic fibrosis lung disease over the next 12 months. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |